Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors.

SINE XPO1 gynecologic cancer leukemia metastatic cancer multiple myeloma selinexor soft tissue sarcoma target therapy

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
20 Sep 2021
Historique:
received: 06 07 2021
revised: 15 09 2021
accepted: 16 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically interesting drugs that targets XPO1 in clinical development. In this review, we summarized the most relevant preclinical and clinical results achieved for non-solid tumors, sarcomas, and other kind of solid tumors.

Identifiants

pubmed: 34575598
pii: pharmaceutics13091522
doi: 10.3390/pharmaceutics13091522
pmc: PMC8466603
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Mol Cancer Ther. 2014 Mar;13(3):675-86
pubmed: 24431073
JAMA. 2020 Apr 7;323(13):1266-1276
pubmed: 32259228
Clin Invest Med. 2009 Dec 01;32(6):E315
pubmed: 20003838
Blood. 2012 Nov 29;120(23):4621-34
pubmed: 23034282
Crit Rev Eukaryot Gene Expr. 2019;29(5):413-424
pubmed: 32421998
BMC Cancer. 2015 Dec 01;15:941
pubmed: 26620414
Exp Cell Res. 2007 Feb 1;313(3):627-37
pubmed: 17182034
J Biol Chem. 2000 Dec 8;275(49):38589-96
pubmed: 10991937
J Biol Chem. 2004 Dec 31;279(53):56061-6
pubmed: 15513923
Chem Biol. 2015 Jan 22;22(1):107-16
pubmed: 25579209
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
J Thorac Oncol. 2017 Sep;12(9):1446-1450
pubmed: 28647672
Oncol Rep. 2009 Jan;21(1):229-35
pubmed: 19082467
PLoS One. 2014 Dec 02;9(12):e113867
pubmed: 25461627
J Cancer Res Clin Oncol. 2021 Jul;147(7):2025-2033
pubmed: 33856525
Biochem Pharmacol. 2018 Jan;147:93-103
pubmed: 29155058
Cancer. 2016 Mar 15;122(6):868-74
pubmed: 26710211
Blood. 2017 Jun 15;129(24):3165-3174
pubmed: 28336527
Blood. 2013 Oct 24;122(17):3034-44
pubmed: 23970380
EMBO J. 1997 Nov 3;16(21):6535-47
pubmed: 9351834
Cancer Sci. 2014 Jul;105(7):795-801
pubmed: 24766216
Int J Mol Sci. 2019 Sep 28;20(19):
pubmed: 31569391
J Clin Oncol. 2016 Dec;34(34):4142-4150
pubmed: 26926685
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Future Oncol. 2021 Aug;17(22):2923-2939
pubmed: 33855868
Br J Cancer. 2014 Jul 15;111(2):281-91
pubmed: 24946002
Oncol Res Treat. 2018;41(7-8):472-477
pubmed: 29895025
Biochemistry (Mosc). 2007 Dec;72(13):1439-57
pubmed: 18282135
Mol Cancer Ther. 2015 Jul;14(7):1570-81
pubmed: 25934708
Gynecol Oncol. 2020 Feb;156(2):308-314
pubmed: 31822399
Blood. 2017 Jun 15;129(24):3175-3183
pubmed: 28468797
J Biol Chem. 2010 Feb 19;285(8):5594-605
pubmed: 20018851
Cancer. 2008 Apr 15;112(8):1733-43
pubmed: 18306389
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Int J Cancer. 2009 Apr 15;124(8):1829-40
pubmed: 19117056
Neurosurgery. 2009 Jul;65(1):153-9; discussion 159-60
pubmed: 19574837
Nat Cell Biol. 2000 Sep;2(9):653-60
pubmed: 10980707
J Cell Biol. 1996 Dec;135(6 Pt 1):1457-70
pubmed: 8978815
Eur J Cancer. 2019 Sep;119:151-157
pubmed: 31442817
J Biol Chem. 2009 Sep 11;284(37):24816-24
pubmed: 19589781
Mol Cancer Ther. 2013 Jul;12(7):1171-9
pubmed: 23615632
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2587-91
pubmed: 8146159
J Clin Oncol. 2002 Jun 15;20(12):2824-31
pubmed: 12065559
Ann Surg Oncol. 2017 Aug;24(8):2145-2154
pubmed: 28397189
Gastroenterology. 2013 Feb;144(2):447-456
pubmed: 23089203
Blood. 2013 May 16;121(20):4166-74
pubmed: 23564911
Nature. 2000 Aug 31;406(6799):1009-12
pubmed: 10984057
EMBO J. 1999 Mar 15;18(6):1660-72
pubmed: 10075936
Oncotarget. 2016 Mar 29;7(13):16581-92
pubmed: 26918731
J Comput Aided Mol Des. 2012 Nov;26(11):1217-28
pubmed: 23053738
Neuro Oncol. 2015 May;17(5):697-707
pubmed: 25366336
Oncotarget. 2014 Jan 15;5(1):11-28
pubmed: 24429466
Blood. 2013 Oct 24;122(17):2926-8
pubmed: 24159164
Lancet. 2020 Nov 14;396(10262):1563-1573
pubmed: 33189178
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336

Auteurs

Antonella Lucia Marretta (AL)

Department of Clinical and Surgery Oncology Unit, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy.

Giuseppe Di Lorenzo (G)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.

Dario Ribera (D)

Department of Clinical and Surgery Oncology Unit, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy.

Lucia Cannella (L)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.

Claudia von Arx (C)

Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.

Alessandra Bracigliano (A)

Nuclear Medicine Unit, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", Via M. Semmola 53, 80131 Naples, Italy.

Ottavia Clemente (O)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.

Roberto Tafuto (R)

Division of Neurosurgery, University of Naples "Federico II", Via S. Pansini 5, 80131 Naples, Italy.

Antonio Pizzolorusso (A)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.

Salvatore Tafuto (S)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.

Classifications MeSH